Towards a solution to MERS : protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein
The Middle-East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe and often fatal respiratory disease in humans. Efforts to develop antibody-based therapies have focused on neutralizing antibodies that target the receptor binding domain of the viral spike protein thereby blocking receptor binding. Here, we developed a set of human monoclonal antibodies that target functionally distinct domains of the MERS-CoV spike protein. These antibodies belong to six distinct epitope groups and interfere with the three critical entry functions of the MERS-CoV spike protein: sialic acid binding, receptor binding and membrane fusion. Passive immunization with potently as well as with poorly neutralizing antibodies protected mice from lethal MERS-CoV challenge. Collectively, these antibodies offer new ways to gain humoral protection in humans against the emerging MERS-CoV by targeting different spike protein epitopes and functions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Emerging microbes & infections - 8(2019), 1 vom: 01., Seite 516-530 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Widjaja, Ivy [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies |
|---|
| Anmerkungen: |
Date Completed 26.06.2019 Date Revised 09.05.2020 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1080/22221751.2019.1597644 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM295601930 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM295601930 | ||
| 003 | DE-627 | ||
| 005 | 20231225084022.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/22221751.2019.1597644 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0985.xml |
| 035 | |a (DE-627)NLM295601930 | ||
| 035 | |a (NLM)30938227 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Widjaja, Ivy |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Towards a solution to MERS |b protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 26.06.2019 | ||
| 500 | |a Date Revised 09.05.2020 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a The Middle-East respiratory syndrome coronavirus (MERS-CoV) is a zoonotic virus that causes severe and often fatal respiratory disease in humans. Efforts to develop antibody-based therapies have focused on neutralizing antibodies that target the receptor binding domain of the viral spike protein thereby blocking receptor binding. Here, we developed a set of human monoclonal antibodies that target functionally distinct domains of the MERS-CoV spike protein. These antibodies belong to six distinct epitope groups and interfere with the three critical entry functions of the MERS-CoV spike protein: sialic acid binding, receptor binding and membrane fusion. Passive immunization with potently as well as with poorly neutralizing antibodies protected mice from lethal MERS-CoV challenge. Collectively, these antibodies offer new ways to gain humoral protection in humans against the emerging MERS-CoV by targeting different spike protein epitopes and functions | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Coronavirus | |
| 650 | 4 | |a MERS | |
| 650 | 4 | |a antibodies | |
| 650 | 4 | |a spike protein | |
| 650 | 7 | |a Antibodies, Monoclonal |2 NLM | |
| 650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 650 | 7 | |a Epitopes |2 NLM | |
| 650 | 7 | |a Receptors, Virus |2 NLM | |
| 650 | 7 | |a Spike Glycoprotein, Coronavirus |2 NLM | |
| 700 | 1 | |a Wang, Chunyan |e verfasserin |4 aut | |
| 700 | 1 | |a van Haperen, Rien |e verfasserin |4 aut | |
| 700 | 1 | |a Gutiérrez-Álvarez, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a van Dieren, Brenda |e verfasserin |4 aut | |
| 700 | 1 | |a Okba, Nisreen M A |e verfasserin |4 aut | |
| 700 | 1 | |a Raj, V Stalin |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Wentao |e verfasserin |4 aut | |
| 700 | 1 | |a Fernandez-Delgado, Raul |e verfasserin |4 aut | |
| 700 | 1 | |a Grosveld, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a van Kuppeveld, Frank J M |e verfasserin |4 aut | |
| 700 | 1 | |a Haagmans, Bart L |e verfasserin |4 aut | |
| 700 | 1 | |a Enjuanes, Luis |e verfasserin |4 aut | |
| 700 | 1 | |a Drabek, Dubravka |e verfasserin |4 aut | |
| 700 | 1 | |a Bosch, Berend-Jan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Emerging microbes & infections |d 2012 |g 8(2019), 1 vom: 01., Seite 516-530 |w (DE-627)NLM249608804 |x 2222-1751 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2019 |g number:1 |g day:01 |g pages:516-530 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/22221751.2019.1597644 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2019 |e 1 |b 01 |h 516-530 | ||